This post was originally published on this site
https://d1-invdn-com.investing.com/content/pic015067c80f65426d662c15ca1d9ffcef.pngWhen this news comes out, InvestingPro users will be getting word of it in real time. Start your 7-day free trial to see for yourself.
Keep an eye on X4 Pharma (NASDAQ:XFOR) on Tuesday, as the company is set to host a presentation of additional Phase 3 data for mavorixafor, its candidate for WHIM Syndrome.
The company had already reported positive Phase 3 results for the drug back in November 2022, and mavorixafor achieved both primary and key secondary endpoints. Nonetheless, investors appear hyped up for the upcoming presentation, as shares have rocketed 80% since early April.
XFOR said it remains on track to submit a New Drug Application (NDA) to the FDA early in the second half of 2023. The stock currently has 11 Buy ratings from various analysts with an average price target of $3.50.
Shares were recently changing hands at $1.47.
Krystal Biotech (NASDAQ:KRYS) is gearing up for the PDUFA of B-VEC, its candidate to treat Epidermolysis Bullosa, on Friday. The company previously had the review date of Feb. 17, although that got pushed back to this coming Friday, May 19, following submission of additional manufacturing data to the FDA.
Heading into the decision, shares are up about 15% year to date to $88.16.
A total of 12 analysts currently cover the company, all with a Buy rating, and an average price target of $115.
Most recently, Stifel initiated coverage with a $102 price target, and called the B-VEC readout an “important milestone that we think warrants optimism.”
Another PDUFA is scheduled for next weekend: Epcoritamab, a drug co-developed by AbbVie (NYSE:ABBV) and Genmab (NASDAQ:GMAB) to potentially treat diffuse large B-cell lymphoma, commonly known as DLBCL, is set for review next Sunday.
ABBV currently has 19 Buy ratings, 13 Holds, and 2 Sells. Its shares are down some 9% year to date to $147.15.
Genmab is up 3% from the start of the year to $41.69.
Last, but not least, American Society of Gene Cell Therapy (ASGCT) will be holding its 26th annual meeting from Tuesday to Saturday, and multiple companies are set to provide updates and release new data bits over the course of the meeting – which InvestingPro subscribers will receive in real time:
Tuesday, May 16:
Wednesday, May 17:
Thursday, May 18:
Friday, May 19:
Saturday, May 20:
Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.
Start your free 7-day trial now.
